Invention Grant
- Patent Title: Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
-
Application No.: US17773607Application Date: 2020-10-28
-
Publication No.: US12054497B2Publication Date: 2024-08-06
- Inventor: Fusheng Zhou , Tao Jiang , Chonglan Lin , Lijian Cai , Wan He , Jiong Lan
- Applicant: GENFLEET THERAPEUTICS (SHANGHAI) INC. , ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
- Applicant Address: CN Shanghai
- Assignee: Genfleet Therapeutics (Shanghai)Inc.,Zhejiang Genfleet Therapeutics Co., Ltd.
- Current Assignee: Genfleet Therapeutics (Shanghai)Inc.,Zhejiang Genfleet Therapeutics Co., Ltd.
- Current Assignee Address: CN Shanghai; CN Shaoxing
- Agency: Morrison & Foerster LLP
- Priority: CN 1911045542.X 2019.10.30 CN 2010272563.1 2020.04.09 CN 2011140832.5 2020.10.22
- International Application: PCT/CN2020/124226 2020.10.28
- International Announcement: WO2021/083167A 2021.05.06
- Date entered country: 2022-04-30
- Main IPC: C07D471/22
- IPC: C07D471/22 ; A61K31/4985 ; A61K31/5383 ; A61K31/55 ; A61P35/00 ; C07D471/14 ; C07D471/16 ; C07D498/22
Abstract:
A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
Public/Granted literature
Information query
